The Optava line of eye care products is part of the portfolio of AbbVie, a global biopharmaceutical company, following its acquisition of the original manufacturer, Allergan.

Optava Company Ownership

Current Owner:
AbbVie, an American publicly traded biopharmaceutical company, now owns the Allergan eye care portfolio, which includes the Optava brand. AbbVie focuses on research and development of advanced therapies for complex and serious diseases.

Original Manufacturer:
The Optava products were originally developed and branded by Allergan, Inc., a pharmaceutical company with a specific focus on eye care, medical aesthetics, and central nervous system products.

Operational Structure:
While now under the AbbVie umbrella, many products in Europe and other regions still carry the “Optava Allergan” name or are distributed by AbbVie local subsidiaries like AbbVie Spain S.L.U..

Optava Product Description

The Optava products you listed are part of a range of lubricating and osmoprotective solutions designed to provide long-lasting relief from dry eye symptoms.

Mechanism:
They use a dual-action formula that both lubricates the eye surface and helps restore the natural osmotic balance of the ocular surface cells.

Key Ingredients:
Common ingredients across the product line include sodium carboxymethyl cellulose (CMC) and glycerin for lubrication, and levocarnitine and erythritol as osmoprotectants. The Optava Fusion and Optava Advance variants also incorporate hyaluronic acid (HA) for enhanced, long-lasting hydration and protection.

Usability:
Most Optava products, particularly the single-dose “UD” (unit-dose) formats, are preservative-free and suitable for use with contact lenses and after laser eye surgery.